Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 17, 2007

Crucell Inks Research License Agreement with ProFibrix on STAR

  • Crucell entered into a nonexclusive STAR® research license agreement with ProFibrix covering the production of specific forms of human fibrinogen.

    According to Crucell, STAR technology is a production method that is particularly useful for the production of recombinant human antibodies and proteins.

  • You’re all set! Thank you for subscribing to GEN Highlights.